<DOC>
	<DOC>NCT00116389</DOC>
	<brief_summary>The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.</brief_summary>
	<brief_title>Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Men or women age ≥18 years Histologically confirmed metastatic (stage IV) adenocarcinoma of the pancreas Measurable disease defined per RECIST Karnofsky Performance Status ≥50 Expected survival ≥12 weeks Provide written informed consent CNS metastases Prior treatment with other chemotherapy for pancreatic cancer unless used as a radiosensitizer Radiation therapy to &gt;25% of the bone marrow Clinically significant laboratory abnormalities Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or nonmetastatic squamous cell carcinoma of the skin, and carcinoma insitu of the cervix The need for chronic (i.e., &gt;7 days) oral or intravenous corticosteroid therapy with &gt;10mg/day prednisone equivalents Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol Patients who are within 28 days of radiation therapy, biologic therapy, immunotherapy, or other investigational medication. All side effects of prior treatment must have resolved at study entry. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>cancer of the pancreas</keyword>
	<keyword>adenocarcinoma of the pancreas</keyword>
	<keyword>pancreatic neoplasms</keyword>
	<keyword>Metastatic pancreatic cancer (Stage IV)</keyword>
	<keyword>Stage IV Adenocarcinoma of the Pancreas</keyword>
</DOC>